Back

Celldex price target raised to $88 after Phase III barzolvolimab results

Verifying
  • Leerink Partners raised Celldex Therapeutics’ price target after barzolvolimab Phase III results.
  • The target increased from $70 to $88 following the trial outcome.
  • Barzolvolimab trials met all primary endpoints in chronic spontaneous urticaria.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.